Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut-Brain hope: probiotic trial targets depression

NCT ID NCT07667530

Symptom relief Sponsor: University of Reading Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a probiotic supplement called Ecologic® Barrier for 16 weeks can reduce depressive symptoms and change brain activity in adults aged 25-40 with mild-to-moderate depression. Participants will be randomly assigned to receive the probiotic or a placebo. The goal is to see if this supplement offers a safe, non-drug way to ease depression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotic supplement (Ecologic® Barrier)
What this could lead to
If it works, this could point toward a simple, non-drug option to help manage mild-to-moderate depression.
What could go wrong
This is an early-stage study with only 76 people, so results may not apply widely. The supplement may have no effect on mood or brain activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 76 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mild to moderate depression symptoms (BDI-II 12-28) * Males and females * Age range will be 25-40 years * Right-handed participants only (required for EEG) Exclusion Criteria: * Taking antidepressants (up to 2 months prior to inclusion) * Undergoing psychological treatment in the form of counselling, therapy or similar (up to 1 month prior to inclusion) * Any diagnosed chronic medical condition (e.g. diabetes) or psychiatric illness. * Use of antibiotics or laxatives (up to 3 months prior to inclusion) * Use of probiotics and/or prebiotics (up to 1 month prior to inclusion) * Enrolled in any other clinical trial (up to 1 month prior to inclusion) * Following restrictive and/or unbalanced diets * Smoking * Continuous use of a weight-loss medication for more than one month prior to screening * Significant gastrointestinal conditions affecting absorption, including but not limited to: inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end-stage renal disease; active cancer or cancer treatment within the past three years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Executive function (cognition) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Executive function (cognition) Mild to moderate depression Neural activity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • School of Psychology and Clinical Languages

    London, RG6 6UR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.